Kytopen develops a non-viral gene delivery platform, Flowfect®, that utilizes continuous fluid flow and electric fields to efficiently deliver mRNA, DNA, and CRISPR Cas9 RNP to billions of cells in minutes. This technology addresses the challenges of cell therapy manufacturing by enabling scalable and customizable transfection processes from discovery to large-scale production.
Funding
$1.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NIFounders
Product
Problem
Current cell therapy manufacturing processes face challenges in efficiently delivering genetic material to cells, hindering scalability and increasing costs from discovery to large-scale production. Traditional methods often struggle with maintaining cell functionality and achieving consistent results across different scales.
Solution
Kytopen's Flowfect® platform addresses these challenges by using continuous fluid flow and electric fields to deliver payloads like mRNA, DNA, and CRISPR Cas9 RNP to billions of cells in minutes. This non-viral gene delivery method enables customizable transfection processes, allowing researchers and developers to optimize conditions and scale production seamlessly. The technology's tunability maximizes yields of engineered therapeutics while retaining cell functionality. Flowfect® facilitates predictive scaling from small-volume experiments to large-volume manufacturing, saving time and reducing costs associated with cell therapy development.
Target Audience
Kytopen's primary customers are researchers and developers in the cell therapy field, particularly those involved in drug discovery, screening, process optimization, and large-scale manufacturing of cell-based therapeutics.
Features
- Continuous flow transfection that retains cell functionality
- Automated platform for high-throughput screening and process optimization
- Tunable parameters to fine-tune delivery for up to 96 samples in a single experiment
- Predictive scaling from small-volume to large-volume manufacturing
- Closed-system transfection instrument compatible with standard cell therapy bioprocessing bags
- Flexibility in volume and delivery speed, processing 10-50 million cells per mL at 25-50 mL per minute
- Compatible with standard liquid handling consumables, such as HSP96 96-well plates